Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
MY TRIALS
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Register a trial
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT05902767
Registration number
NCT05902767
Ethics application status
Date submitted
18/05/2023
Date registered
15/06/2023
Titles & IDs
Public title
Nut Supplementation to Mitigate Post-stroke Cognitive Decline
Query!
Scientific title
Nut Supplementation to Mitigate Post-stroke Cognitive Decline (NUT-me): a Pilot Study
Query!
Secondary ID [1]
0
0
NUT-me
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
NUT-me
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Stroke
0
0
Query!
Dementia
0
0
Query!
Condition category
Condition code
Stroke
0
0
0
0
Query!
Haemorrhagic
Query!
Stroke
0
0
0
0
Query!
Ischaemic
Query!
Neurological
0
0
0
0
Query!
Dementias
Query!
Neurological
0
0
0
0
Query!
Alzheimer's disease
Query!
Mental Health
0
0
0
0
Query!
Other mental health disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Other interventions - Nuts
Other interventions - Control
Experimental: Nut Group - Participants will receive a supply of mixed nuts containing: 1 Brazil nut (\~3g), walnuts (15g), hazelnuts (7g), and almonds (7g) to be consumed daily for 90 days. They will also receive dietary counselling on how to follow the Australian Dietary Guidelines.
Other: Control Group - Participants will follow the same protocol as the Nut group regarding appointments and collection of information. At the visits, they will receive dietary counselling on how to follow the Australian Dietary Guidelines
Other interventions: Nuts
* A mix of nuts containing 1 Brazil nut (\~3g), walnuts (15g), hazelnuts (7g), and almonds (7g) to be consumed daily for 90 days.
* Dietary counselling on how to follow the Australian Dietary Guidelines
Other interventions: Control
- Dietary counselling on how to follow the Australian Dietary Guidelines
Query!
Intervention code [1]
0
0
Other interventions
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Cognitive Function Composite Score
Query!
Assessment method [1]
0
0
Cognitive performance after the 90-day intervention will be assessed in comparison to baseline by using the NIH Toolbox Cognition Battery V3. This validated battery encompasses 15 tests that are combined to generate composite scores by age: Crystalised Composite (which includes picture vocabulary and oral reading recognition tests) and Fluid Composite (which includes dimensional change card sort, flanker, picture sequence memory, list sorting, and pattern comparison tests).The Cognitive Function Composite Score is a combination of both crystallized and fluid scores. Higher scores indicate better cognitive performance.
Query!
Timepoint [1]
0
0
90 days
Query!
Secondary outcome [1]
0
0
Fluid Cognition Composite Score
Query!
Assessment method [1]
0
0
Cognitive performance after the 90-day intervention will be assessed in comparison to baseline by using the NIH Toolbox Cognition Battery V3. This validated battery encompasses 15 tests that are combined to generate composite scores by age: Crystalised Composite (which includes picture vocabulary and oral reading recognition tests) and Fluid Composite (which includes dimensional change card sort, flanker, picture sequence memory, list sorting, and pattern comparison tests).The Cognitive Function Composite Score is a combination of both crystallized and fluid scores. Higher scores indicate better cognitive performance.
Query!
Timepoint [1]
0
0
90 days
Query!
Secondary outcome [2]
0
0
Crystallized Cognition Composite Score
Query!
Assessment method [2]
0
0
Cognitive performance after the 90-day intervention will be assessed in comparison to baseline by using the NIH Toolbox Cognition Battery V3. This validated battery encompasses 15 tests that are combined to generate composite scores by age: Crystalised Composite (which includes picture vocabulary and oral reading recognition tests) and Fluid Composite (which includes dimensional change card sort, flanker, picture sequence memory, list sorting, and pattern comparison tests).The Cognitive Function Composite Score is a combination of both crystallized and fluid scores. Higher scores indicate better cognitive performance.
Query!
Timepoint [2]
0
0
90 days
Query!
Secondary outcome [3]
0
0
% body fat
Query!
Assessment method [3]
0
0
Changes in % body fat measured using bioelectrical Impedance Analysis (BIA)
Query!
Timepoint [3]
0
0
90 days
Query!
Secondary outcome [4]
0
0
Depressive symptoms
Query!
Assessment method [4]
0
0
Changes in the presence of depressive symptoms assessed by Patient Health Questionnaire (PHQ-9). The score ranges from zero to 27, with higher scores indicating worse depressive symptoms.
Query!
Timepoint [4]
0
0
90 days
Query!
Secondary outcome [5]
0
0
HOMA-IR
Query!
Assessment method [5]
0
0
HOMA-IR is a measure of insulin resistance. It is calculated according to the formula: fasting insulin (microU/L) x fasting glucose (nmol/L)/22.5.
Query!
Timepoint [5]
0
0
90 days
Query!
Secondary outcome [6]
0
0
Blood lipids
Query!
Assessment method [6]
0
0
Changes in total cholesterol, LDL, HDL and triglycerides
Query!
Timepoint [6]
0
0
90 days
Query!
Secondary outcome [7]
0
0
Inflammatory markers
Query!
Assessment method [7]
0
0
Changes in the composite of the following inflammatory markers: IL-6, IL-1ß, IL-8, IL-10, and IL-1ra
Query!
Timepoint [7]
0
0
90 days
Query!
Eligibility
Key inclusion criteria
* Ischaemic stroke (first or recurrent stroke) in the last 6 months
* Able to attend 4 study visits over 3 months
* Motivation and willingness to participate in the study protocol
* No prior neurological or psychiatric disease, including dementia
* Can give informed consent and participate in cognitive testing
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
99
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* be < 18 years;
* have allergy to nuts
* have premorbid modified Rankin scale (mRS)=4, denoting no severe disability
* incapable of giving consent
* have problems with mastication that preclude nut intake
* have habitual consumption of tree nuts (>2 servings/wk) in the previous 2 months
* have habitual consumption of alpha-linolenic acid supplements (fish oil, flaxseed oil, and/or soy lecithin)
* have dementia or psychiatric disease
* do not speak English
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
NA
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
30/06/2023
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
30/12/2025
Query!
Actual
Query!
Sample size
Target
10
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
VIC
Query!
Recruitment hospital [1]
0
0
Department of Nutrition, Dietetics and Food - Monash University - Melbourne
Query!
Recruitment postcode(s) [1]
0
0
3168 - Melbourne
Query!
Funding & Sponsors
Primary sponsor type
Other
Query!
Name
Monash University
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
Stroke is a strong risk factor for dementia, with up to 80% of individuals having lower cognitive function 5 years after a stroke event. However, having a stroke does not need to result in declining cognition if effective strategies to reduce the risk of post stroke dementia are identified. Diets containing nuts can reduce the risk of both dementia and stroke but have not been tested in stroke survivors. Therefore, this pilot study aims to determine whether eating nuts regularly reduces post-stroke cognitive decline and dementia. The NUT-me pilot study will supplement the diet of stroke survivors with a mix of nuts containing walnuts, hazelnuts, almonds and Brazil nuts for 3 months and assess the effects on cognition and health markers. The researchers predict that regular nut consumption will contribute to preserving post-stroke cognitive function in comparison to patients who do not consume nuts. The results of this novel pilot study will be used to guide a larger trial and provide a simple dietary strategy that stroke survivors can adopt to reduce post-stroke cognitive decline.
Query!
Trial website
https://clinicaltrials.gov/study/NCT05902767
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Barbara R Cardoso, PhD
Query!
Address
0
0
Department of Nutrition, Dietetics and Food - Monash University
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Barbara R Cardoso, PhD
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
+61499840472
Query!
Fax
0
0
Query!
Email
0
0
[email protected]
Query!
Contact person for scientific queries
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
Query!
No/undecided IPD sharing reason/comment
This is a small pilot study and the generated data will be used only by the Principal Investigator as preliminary data in grant applications and potentially one publication (yet to be decided).
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results not provided in
https://clinicaltrials.gov/study/NCT05902767